Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xiamen Amoytop Biotech CoSHSE:688278 +0.79%76 Return-on-Tangible-Equity is 21.21% as of Mar. 2026, which is 3% below its 10-year median of 21.95. GuruFocus rates SHSE:688278 with a GF Score™ of 76/100 and a GF Value™ of ¥107.23 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 1,199 Biotechnology companies, Xiamen Amoytop Biotech Co ranks better than 93.58% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Xiamen Amoytop Biotech Co's annualized net income for the quarter that ended in Mar. 2026 was ¥658 Mil. Xiamen Amoytop Biotech Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ¥3,101 Mil. Therefore, Xiamen Amoytop Biotech Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 21.21%.
The historical rank and industry rank for Xiamen Amoytop Biotech Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:688278'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 2.22 Med: 21.95 Max: 44.77
Current: 37.56
During the past 10 years, Xiamen Amoytop Biotech Co's highest Return-on-Tangible-Equity was 44.77%. The lowest was 2.22%. And the median was 21.95%.
SHSE:688278's Return-on-Tangible-Equity is ranked better than 93.58% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs SHSE:688278: 37.56
Xiamen Amoytop Biotech Co (SHSE:688278) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Xiamen Amoytop Biotech Co Return-on-Tangible-Equity Related Terms
Xiamen Amoytop Biotech Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Xiamen Amoytop Biotech Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xiamen Amoytop Biotech Co Return-on-Tangible-Equity Chart
SHSE:688278 vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Xiamen Amoytop Biotech Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xiamen Amoytop Biotech Co Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xiamen Amoytop Biotech Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Xiamen Amoytop Biotech Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 21.21% mean?
Xiamen Amoytop Biotech Co (SHSE:688278) has a Return-on-Tangible-Equity of 21.21% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Xiamen Amoytop Biotech Co and its competitors. This is near median its historical median of 21.95. Over the past decade, Xiamen Amoytop Biotech Co's Return-on-Tangible-Equity has ranged from 2.22 to 44.77. According to the industry distribution chart, Xiamen Amoytop Biotech Co ranks #77 out of 1199 companies in the Biotechnology industry, placing it in the top 6.4%.
Is Xiamen Amoytop Biotech Co's Return-on-Tangible-Equity too high?
Xiamen Amoytop Biotech Co's current Return-on-Tangible-Equity of 21.21% is near median its 10-year median of 21.95. Over the past 10 years, this metric has ranged from a low of 2.22 to a high of 44.77. Based on the distribution chart, Xiamen Amoytop Biotech Co ranks #77 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Xiamen Amoytop Biotech Co has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xiamen Amoytop Biotech Co's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xiamen Amoytop Biotech Co ranks #77 out of 1199 companies for Return-on-Tangible-Equity. This places Xiamen Amoytop Biotech Co in the top 6% of its industry — outperforming the majority of peers. Historically, Xiamen Amoytop Biotech Co's own Return-on-Tangible-Equity has ranged from 2.22 to 44.77 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Xiamen Amoytop Biotech Co and its competitors. Xiamen Amoytop Biotech Co's current Return-on-Tangible-Equity is 21.21%, which is near median its own 10-year median of 21.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xiamen Amoytop Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Xiamen Amoytop Biotech Co (SHSE:688278) is currently considered Possible Value Trap. The stock's GF Value™ is ¥107.23, compared to a current price of ¥58.35 — trading 45.6% below its estimated fair value. The current Return-on-Tangible-Equity is 21.21%, which is near median its 10-year median of 21.95. Xiamen Amoytop Biotech Co's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Xiamen Amoytop Biotech Co (SHSE:688278), the current Return-on-Tangible-Equity is 21.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xiamen Amoytop Biotech Co (SHSE:688278) Overvalued in 2026?
Based on GuruFocus' analysis, Xiamen Amoytop Biotech Co stock appears to be undervalued.
The current stock price of ¥58.35 is trading 45.6% below its estimated GF Value™ of ¥107.23.
GuruFocus considers Xiamen Amoytop Biotech Co to be Possible Value Trap.
Key valuation signals for SHSE:688278:
Return-on-Tangible-Equity: 21.21% (near median its 10-year median of 21.95)
GF Value™: ¥107.23 vs. price of ¥58.35 (45.6% below fair value)
No single metric tells the full story. See the SHSE:688278 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xiamen Amoytop Biotech Co Ltd operates as a drug development company. The Company develops and sells protein drugs, interferon drugs, and other products.
76GF Score
Get the complete analysis for SHSE:688278
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688278 has been successfully added to your 
